PharmacoEconomics & Outcomes News

, Volume 821, Issue 1, pp 30–30 | Cite as

Teriflunomide more effective, less costly in relapsing MS in China

Clinical study


  1. Xu Y, et al. Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. Clinical Drug Investigation : 25 Jan 2019. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations